noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Patty Murray

Senator Murray on the Latest Status of the Disaster Relief Fund
New York State Office of Mental Health

Governor Hochul Launches Public Awareness Campaign to Educate New[...]
Greenberg Traurig LLP

Greenberg Traurig Accelerates Strategic London Growth with Real Estate[...]

Environment

Krystal Biotech Inc.

10/22/2025 | Press release | Distributed by Public on 10/22/2025 06:02

Material Event (Form 8-K)

Item 8.01 Other Events

Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK®(beremagene geperpavec) in Japan for the treatment of dystrophic epidermolysis bullosa following its inclusion on Japan's National Health Insurance (NHI) Drug Price List on the same date. VYJUVEK has been listed on the NHI Drug Price List at a price of 2,955,232.7 yen per unit. This Current Report on Form 8-K is being furnished for informational purposes only.

Krystal Biotech Inc. published this content on October 22, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on October 22, 2025 at 12:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]